Keros Therapeutics reported a quarterly loss of $1.21 per share, wider than the Zacks Consensus Estimate for a $0.92 loss and sharply below the $3.62 per share earned a year ago. The miss versus expectations and year-over-year deterioration point to weakening fundamentals in the biotech name. The update is likely to pressure the stock, though the overall market impact should remain company-specific.
Keros Therapeutics reported a quarterly loss of $1.21 per share, wider than the Zacks Consensus Estimate for a $0.92 loss and sharply below the $3.62 per share earned a year ago. The miss versus expectations and year-over-year deterioration point to weakening fundamentals in the biotech name. The update is likely to pressure the stock, though the overall market impact should remain company-specific.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly negative
Sentiment Score
-0.46
Ticker Sentiment
